Veracyte Stock News

Man Group plc lifted its holdings in Veracyte, Inc. (NASDAQ:VCYT) by 33.7% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 11,900 shares of the biotechnology companys stock after purchasing an additional 3,000 shares during the quarter. Man Group plcs holdings in Veracyte were []

Prudential Financial Inc. trimmed its stake in shares of Veracyte, Inc. (NASDAQ:VCYT) by 82.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 46,445 shares of the biotechnology companys stock after selling 217,503 shares during the period. Prudential Financial Inc. []

The Goldman Sachs Group began coverage on shares of Veracyte (NASDAQ:VCYT) in a research report report published on Thursday morning, The Fly reports. The firm issued a buy rating and a $59.00 price target on the biotechnology companys stock. A number of other equities analysts also recently commented on the company. TheStreet upgraded Veracyte from []

Equities research analysts predict that Veracyte, Inc. (NASDAQ:VCYT) will announce sales of $62.25 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Veracytes earnings, with estimates ranging from $59.10 million to $65.70 million. Veracyte posted sales of $34.54 million during the same quarter last year, which would indicate []

Veracyte (NASDAQ:VCYT) had its price objective increased by Raymond James from $50.00 to $62.00 in a research report sent to investors on Wednesday morning, The Fly reports. Raymond James currently has an outperform rating on the biotechnology companys stock. VCYT has been the topic of several other research reports. Morgan Stanley lowered their target price []

Veracyte, Inc. (VCYT) CEO Marc Stapley on Q3 2021 Results - Earnings Call Transcript

Veracyte (VCYT) delivered earnings and revenue surprises of 7.14% and 10.44%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--New data to be presented at ASTRO 2021 reinforce the clinical utility of Veracyte's Decipher Prostate genomic classifier

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Data published in the Journal of Urology demonstrate Veracyte's Decipher Bladder test can identify tumors most likely to respond to chemotherapy

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte to Release Third Quarter 2021 Financial Results on November 9, 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Data to be presented at CHEST show Veracyte's Envisia Genomic Classifier positively impacts clinical decision-making in idiopathic pulmonary fibrosis.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces New Expanded Data at CHEST Underscoring Percepta Nasal Swab Test's Ability to Improve Early Lung Cancer Assessment

Shares of the genetic diagnostics company are down nearly 50% from their 52-week high in February.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--New NCCN Guidelines Recommend Use of Veracyte's Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men After Radical Prostatectomy

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte has appointed Dr. Joshua Klopper as Medical Director, Endocrinology.